Glycihold M1 Forte Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, increasing peripheral glucose uptake, and improving insulin sensitivity. The prolonged-release formulation ensures a steady plasma concentration, reducing gastrointestinal side effects commonly associated with immediate-release metformin and enhancing patient compliance. Glycihold M1 Forte is prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels in patients inadequately controlled by monotherapy. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in elderly patients and those with cardiovascular disease. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and rare lactic acidosis. Dose adjustments may be necessary based on clinical response and tolerability. Glycihold M1 Forte Tablet PR should be used under strict medical supervision to optimize therapeutic outcomes in type 2 diabetes management.

Dosage & How to Use